Silihan lan utang jangka dawa perusahaan: Pieris (PIRS)
The daily price chart reflecting the value of Pieris Pharmaceuticals (PIRS) long-term liabilities relies on the neutral geopolitical status of medicine, which shields the company's scientific ties from sanctions. Operational flexibility is achieved through a German R&D center and US-based contract manufacturing. Revenues are based on royalties and upfront payments from global behemoths for the development of protein drugs, with the metric standing at 0.02.
Ringkesan rincian data analitis Pieris (PIRS)
Long-term liabilities determine the financial stability and ability of Pieris Pharmaceuticals (PIRS) to service borrowed capital over a horizon exceeding one year. This metric measures the volume of external financing critical for capital-intensive R&D projects. Assessing the long-term debt of Pieris Pharmaceuticals (PIRS) allows for tracking the borrowing pace used to develop the Anticalin platform and the PRS-220 drug. The stability of this line confirms balanced liquidity management while awaiting partner payments. Monitoring this indicator minimizes bankruptcy risks in the event of clinical trial stagnation.